Expression of DMBT1 in Colorectal Cancer Patients

Colorectal Cancer Clinical Trial

— DMBT1  

Official title:

Modification of the Expression and the Localization of DMBT1 (Deleted in Malignant Brain Tumor 1) in Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02901600
• Other study ID #: RT-06
• Status: Completed
• Phase: N/A
• First received: September 12, 2016
• Last updated: September 12, 2016
• Start date: June 2013
• Est. completion date: November 2015

Study information

• Verified date: September 2016
• Source: Lille Catholic University
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease.

Preliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 145
• Est. completion date: November 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• for colon cancer: patients surgically treated for colorectal cancer at the Group of hospitals of the Catholic Institute of Lille.

• for adenomatous polyps : patients treated for adenomatous polyps at the Group of hospitals of the Catholic Institute of Lille.

• for controls: patients surgically treated for diverticular disease at the Group of hospitals of the Catholic Institute of Lille.

Exclusion Criteria:

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• DMBT1 Protein, Human

Intervention

Other:
• Detection of the expression of DMTB1 by immunohistochemistry

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Lille Catholic University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Semi-quantitative determination of the histological expression of DMBT1	The expression of DMTB1 will be determined by observation of the slides after immunohistochemistry using an anti-DMBT1 antibody	at baseline	No
Primary	Determination of the histological localisation of DMBT1	The localisation of DMTB1 will be determined by observation of slides after immunohistochemistry using an anti-DMBT1 antibody	at baseline	No